Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11645671 | 0.88 | MTNR1A (0.58) | MTNR1AMTNR1BLMNAMAPTMEN1 | |
| SCHEMBL11642610 | 0.88 | MTNR1A (0.58) | MTNR1AMTNR1BLMNAMAPTMEN1 | |
| SCHEMBL4366143 | 0.86 | MTNR1A (0.57) | MTNR1AMTNR1BLMNANR4A1MEN1 | |
| SCHEMBL6516221 | 0.84 | KMT2A (0.73) | MTNR1AMTNR1BLMNAMAPTMEN1 | |
| SCHEMBL3547563 | 0.83 | PKM (0.62) | MTNR1AMTNR1BLMNAMAPTMEN1 | |
| SCHEMBL19559835 | 0.83 | BRAF (0.73) | MTNR1AMTNR1BLMNAMAPTMEN1 | |
| SCHEMBL5352381 | 0.82 | MAPT (0.64) | MTNR1AMTNR1BLMNAMAPTMEN1 | |
| SCHEMBL463887 | 0.81 | MTNR1B (0.71) | MTNR1AMTNR1BLMNAMAPTMEN1 | |
| SCHEMBL7509092 | 0.81 | TDP1 (0.60) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL30442658 | 0.81 | TDP1 (0.60) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875727-B2 | methyl [5(6)-(4-alanylaminophenylthio)-1H-benzimidazol-2yl]carbamate; for treating neovascularization, solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| EP-1140078-B1 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-11-23 | — | — | US | disclosed |
| US-7081469-B2 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-07-25 | — | — | US | disclosed |
| US-20040082583-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20040058972-A1 | Benzimidazole vascular damaging agents | DAVIS PETER DAVID (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1341771-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002044156-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-06-06 | — | — | WO | disclosed |
| EP-1140078-A2 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Ltd (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000041669-A2 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058972-A1 | Benzimidazole vascular damaging agents | FLT1, FLT4, PCNA | MTNR1A 2944/4885MTNR1B 3582/4885LMNA 1447/4885 |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | TIE1, KDR, FLT4 | MTNR1A 2937/4885MTNR1B 1843/4885LMNA 2801/4885 |
| US-20040082583-A1 | Chemical compounds | TIE1, KDR, FLT4 | MTNR1A 2937/4885MTNR1B 1843/4885LMNA 2801/4885 |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | FLT4, PCNA, FLT1 | MTNR1A 3424/4885MTNR1B 3903/4885LMNA 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.